To evaluate if these genes are exclusively predictive of the outcome prognosis in glioma, we examined their role in comparable gene signature panels in other cancer types: A number of genes that are part of glioma risk–models (CARS, FANCD2, HMGCR, NCOA4 and SLC7A11) (46) and (AKR1C1, CARS1, CBS, CD44, CHAC1, DPP4, FANCD2, GOT1, HMGCR, SLC1A5, NCOA4 and STEAP3) (47) also accurately predicted patients’ prognosis in clear renal cell carcinoma. Here, CD44 is linked to central nervous system cancer.